Agilent Technologies “in Country, for Country” Strategy Helps Mitigate Supply Disruptions

Why It Matters

The approach strengthens operational resilience and expands affordable access to high‑end lab equipment, boosting Agilent's market share in a critical region. It also positions the company as a sustainability leader in scientific instrumentation.

Key Takeaways

• In‑country manufacturing reduces supply chain risk
• Refurbished instruments provide affordable, sustainable lab solutions
• India drives 15‑18% of Agilent's revenue growth
• Flexible financing expands market to startups and small labs
• Supply‑chain diversification mitigates geopolitical disruptions

Pulse Analysis

Agilent's "in‑country, for‑country" strategy reflects a broader industry shift toward localized production to counteract geopolitical volatility. By establishing manufacturing and refurbishment capabilities within India, the company shortens shipping routes, lowers exposure to cross‑border logistics bottlenecks, and safeguards critical components from external shocks. This model not only ensures continuity for existing customers but also creates a buffer against future trade restrictions, reinforcing Agilent's reputation for supply‑chain resilience.

The refurbishment centre in Manesar exemplifies Agilent's commitment to sustainability and market accessibility. Certified pre‑owned instruments, restored to factory standards and backed by a one‑year warranty, allow laboratories with limited capital to adopt cutting‑edge technology. Flexible payment structures—subscriptions, rentals, or project‑based financing—further lower entry barriers, fostering adoption among startups and small‑scale labs. This approach aligns with global trends toward circular economy practices, reducing waste while extending product lifecycles.

Financially, the localized strategy supports Agilent's growth trajectory in the Asia‑Pacific region, which now accounts for up to 18% of total revenue. India's burgeoning pharmaceutical and biopharma sectors, especially in CDMO services and GLP‑1 drug production, present a lucrative opportunity. By embedding supply‑chain resilience and affordable solutions, Agilent not only protects its margins but also captures market share from competitors slower to adapt. The combined effect positions the firm as a resilient, innovative leader in scientific tools, poised for sustained expansion.